Closing
Do other lipid agents improve kidney outcomes versus placebo?
Mostly studied in dyslipidaemia.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 1
Already under way
- Utilizing Lipid-lowering Therapy With Moderate-intensity Statin Plus Ezetimibe in Chronic Kidney Disease Patients With Concomitant Atherosclerotic…NCT07524101 · recruiting · started 2026
- Efficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi PopulationNCT06789432 · recruiting · started 2025
- Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined…NCT05365438 · recruiting · started 2022
- Real World Data Observational Study to Evaluate the Management Status of Dyslipidemia Following Administration of Statin and Ezetimibe Complex Treatment…NCT05614765 · active not recruiting · started 2022
- NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury (NACAM) TrialNCT04750616 · recruiting · started 2021
The evidence so far
- Registered trials
- 17
- With posted results
- 2
- Published papers
- 3
Of 1 decided analyses: 0 favor other lipid agents, 1 find no difference, 0 favor the comparator.
Papers
- Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).Trial report · 2016
- Comparative efficacy and choice of lipid-lowering drugs for cardiovascular and kidney outcomes in patients with chronic kidney disease: A systematic review and network meta-analysis.Meta-analysis / systematic review · 2025
- Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.Trial report · 2016
Trials
- A Novel Preoperative Conditioning Therapy in Giant Obese Patients With the Combination of Liraglutide and a Leucine-Based Amino-Acid Infusion and Caloric RestrictionNCT02616003
- Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal ImpairmentNCT00108485 · 1 posted result
- A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate / Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching Monotherapies in Dyslipidemic Subjects at High Risk of Cardiovascular Disease.NCT01674712
- A Multicenter Clinical Trial to Compare the Efficacy and Safety Between Rosuvastatin/Ezetimibe Combination and Monotherapy of Rosuvastatin in Patients With Diabetes Mellitus and HypercholesterolemiaNCT03217409
- A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome.NCT00703755
- A Randomized, Prospective, Double-Blind Study to Evaluate the Effects on Lipid Profile of Combined Ezetimibe and Simvastatin Therapy as Compared to Simvastatin Alone in People With Type 2 DiabetesNCT00157482
- Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined DyslipidemiaNCT05365438
- Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE TrialNCT04626973